Elron Ventures Ltd · TASE:ELRN
Elron Ventures — Merger or Acquisition (July 2020)
22 slides from Elron Ventures's merger presentation, Jul 16, 2020
Slide 1: Elron Announces Transaction for Investment and Option to Acquire CartiHeal
ENGLISH TRANSLATION FROM HEBREW ELRON ANNOUNCES TRANSACTION FOR INVESTMENT AND OPTION TO ACQUIRE CARTIHEAL Investor Presentation, July 16, 2020
Slide 2: Comments
This presentation is for information purposes only. By this presentation, Elron does not intend to solicit offers to purchase its securities and the presentation does not constitute an invitation to receive such offers, and nothing said therein constitutes a “public offering”, as defined in the Isra
Slide 3: Conference Call Participants
CONFERENCE CALL PARTICIPANTS YARON ELAD ZVIKA SLOVIN CEO Head of Medtech Chairman of CartiHeal 3
Slide 4: Transaction Highlights
TRANSACTION HIGHLIGHTS On July 16, 2020 Elron announced the signing of definitive agreements for an investment in CartiHeal Announcement and an option to acquire CartiHeal by Bioventus LLC Transaction • A $15-20M investment in CartiHeal at a pre-money value of $180M, of which $15M was invested immed
Slide 5: Timeline
TIMELINE Statistical report of Investment final trial results PMA by Bioventus Expected: End of submission $100M in 7/2020 2021 to FDA FDA approval revenues Bioventus exercises break- CartiHeal CartiHeal up right Sellers CartiHeal Elron’s Sellers Elron’s $30M payment to share: share: CartiHeal PUT $
Slide 6: Thank You
THANK YOU. elron.com
Slide 7: The Future of Joint Repair
The Future of Joint Repair July 16, 2020
Slide 8: OA of the Joint
OA of the Joint Osteoarthritis (OA) is a slowly progressive disease where cartilage of the synovial joint degenerates
Slide 9: Indications: Cartilage Lesions, Osteochondral Defects & OA in the Knee, Ankle & Great Toe
Indications: Cartilage Lesions, Osteochondral Defects & OA in the Knee, Ankle & Great Toe Ankle Knee Cartilage Osteochondral Lesions Defects Osteoarthritis Great Toe 3
Slide 10: Agili-C – a Solution for an Unmet Need in Joint Preservation
Agili-C – a Solution for an Unmet Need in Joint Preservation Disease Conservative Injections Arthroscopy Natural Joint Resurfacing Replacements & Preservation Severity Partial & Total Severe OA Replacement “bone on bone” Mild – Moderate OA Agili-C Allografts Life style Steroids Debridement change Ca
Slide 11: Agili-C: Bio-Degradable
Agili-C: ee Bio-Degradable
Slide 12: Agili-C Implant: B-Phasic, Bio-degradable
Agili-C Implant: B-Phasic, Bio-degradable MSCs chondrogenicity Cartilage Phase: & native cartilage Modified Porosity ingrowth from periphery Cartilage Bone Bone marrow MSC Bone Phase: adhesion, Natural Porosity differentiation & proliferation 6
Slide 13: Mechanism of Cartilage Formation
Mechanism of Cartilage Formation Goat model Cartilage flow from implant periphery towards the center is enhanced by cartilage formation from the drilled holes 7
Slide 14: Large Trochlea Osteochondral Defect
Large Trochlea Osteochondral Defect Male, 18yr X-ray 24 MRI 24 Pre-op MRI Implantation month post op month post op Baseline 6M 12M 18M 24M KOOS Pain 38 74 92 100 100 KOOS Overall 46 81 90 100 100 Prof. Elizaveta Kon, Italy
Slide 15: https://ryortho.com/ - gnttieg/ 2019/05 / sraey - 25 - refta - thgir - riaper
https://ryortho.com/-gnttieg/2019/05 /sraey-25-refta-thgir-riaper-egaltirac
Slide 16: IDE Pivotal Study: CLN0021 Overview
IDE Pivotal Study: CLN0021 Overview Agili-C™ vs. Surgical Standard of Care (SSOC) for the Treatment of Joint Surface Lesions of the Knee Primary Endpoint: To demonstrate the superiority of Agili-C vs. SSOC (MFX & Debridement) according to change from baseline to 24 months in the average overall KOOS
Slide 17: Standard of Care
Standard of Care Debridement Microfracture
Slide 18: Agili-C Implant
meee Agili-C Implant
Slide 19: KOOS Score
KOOS Score Knee injury and Osteoarthritis Outcome Score (KOOS)
Slide 20: Randomized Controlled Study, an approximate diagram
Randomized Controlled Study, an approximate diagram Baseline Treated Arm 24M KOOS(24M) – KOOS(BS) KOOS Agili-C KOOS VISIT I P ≤ 0.02 P ≤ 0.02 Baseline Control Arm 24M KOOS KOOS KOOS(24M) – KOOS(BS) Surgical Standard of Care
Slide 21: Regulatory Application Process
Regulatory Application Process Interim Analysis >95% 250 Pts PMA FDA FDA CE Study Pivotal Trial Clinical Submission Review Approval PMA Manufacturing Submission PMA Non-clinical Submission
Slide 22: Thank You
Thank You CONFIDENTIAL Pivotal study Dec 2016 16